Dyspnoea and Thoracic Spinal Deformation in Rats after Oral Prizidilol (SK&F 92657-A2)

Abstract

<jats:p> Prizidilol (SK&amp;F 92657-A2), an anti-hypertensive agent, has undergone a range of prescribed toxicity studies required for the investigation of possible adverse drug effects. During the second year of the 2-year rat oral study, a variety of symptoms were exhibited by males receiving 1600 mg of the compound day<jats:sup>–1</jats:sup>kg<jats:sup>–1</jats:sup> by gavage. These animals became lethargic, slouched and developed dyspnoea which became progressively more severe during the course of the study. Necropsy of the affected rats revealed severely haemorrhagic lungs, cardiac hypertrophy and lordosis of the spine into the thoracic cavity. At the 2-year terminal kill, a proportion of the male rats receiving 100 and 400 mg of prizidilol day<jats:sup>–1</jats:sup>kg<jats:sup>–1</jats:sup> were identified with similar but less severe spinal deformation. No female was found with spinal changes but all the rats receiving prizidilol showed haemorrhagic lungs and enlarged hearts. The lordosis of the affected males was always confined to the thoracic spine and this, along with the cardiac hypertrophy, presumably led to marked reduction in the volume of the thoracic cavity, inducing the dyspnoea. Thoracic vertebral body damage, possibly a precursor to the spinal deformities, was found in male rats from both drug-treated and control groups. The nature of the spinal lesion is at present under investigation. </jats:p>

Respiratory Tract

“…Although the mechanisms were not explored in detail, a diffuse interstitial pulmonary inflammatory process with lung hemorrhage was induced in rats treated for two years with prizidilol (SK&F 92657-A2), an antihypertensive agent with both vasodilator and β adenoceptor blocking properties. 161 Affected animals developed dyspnea associated with reduction in lung volume, deformity of the thoracic spinal column and marked cardiac hypertrophy.…”